Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
Everyday Health3 天
Magnesium Deficiency Signs and Symptoms
If there were a do-it-all nutrient award, it might go to magnesium. The humble mineral plays a critical role in helping your body function successfully. “Aside from being a component of our ...
The Pharma Letter6 天
Positive Phase III ACTIVATE-Kids study of Agios’ mitapivat
USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.